New drug for paediatric nonverbal disorder developed

Biotechnology acceleration company, Q BioMed, has announced its successful development of a new and proprietary analogue of QBM-001 in partnership with Sphaera Pharma for paediatric nonverbal disorder.

“We are very pleased to have successfully reached our developmental milestone with great results thus far, putting us in position to help these young children as well as their parents and caregivers,” explained Denis Corin, CEO of Q BioMed. “We are highly motivated to develop a drug and delivery system that will accommodate their very specific needs. As a result of meeting this milestone, we are now in a position to move QBM-001 into the clinic as quickly as possible.”

The novel analogue was selected from an array of candidates that Sphaera Pharma's patented platform produced and QBM-001's pharmacodynamics demonstrated the best improvement in safety without compromising efficacy. Completion of the complete panel of preclinical testing is expected in January 2018 and Q BioMed is simultaneously pursuing cGMP manufacturing and regulatory filings in preparation for the IND.